Diet supplements sit in a special, largely unregulated niche in the U.S. health market that poses real dangers to consumers who assume the products are safe, effective or checked out by federal regulators. Unlike prescription medications, supplements don’t need approval from the Food and Drug Administration (or the FDA) before they reach the market. Manufacturers don’t need to prove safety or efficacy before their products hit store shelves. Harvard Health , for instance, says the overwhelming majority of supplements are of little proven benefit, frequently contain inconsistent or contaminated ingredients, and are sold with claims that mislead consumers about their therapeutic value. This regulatory vacuum has created a fertile ground for potentially dangerous substances to flourish, with the case of kratom providing a textbook example of how consumers can be placed at substantial health risk.
Kratom comes from the leaves of Mitragyna speciosa and is sold in the United States as a natural remedy for pain, anxiety and opioid withdrawal. However, kratom products are not legally marketed as dietary supplements. The FDA has said that kratom is a “new dietary ingredient,” for which there is insufficient evidence to establish safety, meaning that supplements containing kratom are adulterated under federal law. But kratom is still widely available online and in retail stores, highlighting how weak enforcement and regulatory loopholes let unsafe products reach consumers.
The risks are further highlighted in scientific literature. More than 50 alkaloids have been found in kratom, including mitragynine and 7-hydroxymitragynine (7-OH), which have been shown to have complex pharmacological effects that are potent, according to a review in Frontiers in Pharmacology . Research shows kratom can act on the same receptors as opioids and carries risks of addiction, dependence and toxicity, though it is often portrayed as a benign herbal remedy. Another study says kratom’s growing availability in the U.S. since the early 2000s has come during a time when little was known about its pharmacology or long‑term effects, leaving consumers susceptible to unrecognised harms.
The FDA has repeatedly warned the public about the dangers of kratom. The agency points out that 7-OH, a minor constituent of natural kratom leaves, is much more potent than morphine at the mu-opioid receptor. The potency of these products raises concerns about overdose, particularly as some have been found to contain concentrated or synthetic versions of 7-OH. Federal officials have been looking into kratom for nearly 10 years, following reports of addiction, injury and death associated with the plant. Still, kratom remains readily available due to larger regulatory weaknesses that apply to supplements.
The impact of this regulatory gap extends beyond kratom. The AMA says supplements can contain harmful contaminants, inaccurate dosages or pharmacologically active ingredients not listed on the label.Besides the sometimes outrageous health claims these brands make, such as getting well over a safe dose of a substance in just 1 pill and suffering because of it, the lack of proper information for consumers about these supplements can lead to many people having serious medical issues. Harvard Health also warns that consumers often think supplements are safe because they are “natural,” but many products have been tied to liver injury, cardiovascular events and dangerous interactions with medications. Without the benefit of pre-market testing, consumers are the unwitting test subjects of products with unknown risks.
Kratom is an example of how these systemic failures play out. Supplements are not subject to rigorous safety testing, so kratom products are being released to the market without adequate toxicological testing. Millions of Americans now use kratom despite inadequate data on its long-term safety, addiction potential, or interactions with other substances. The lack of regulation also results in inconsistent product quality; some kratom products contain adulterants or high levels of 7OH, which increases overdose risk.
These negative consequences are exacerbated by the use of misleading marketing to promote Kratom. Kratom has been promoted as a superior, safer replacement for prescription opioids and as an alternative method for treating withdrawal symptoms; however, there is no scientific evidence to support any of those claims made by dealers selling Kratom. The FDA has previously issued warnings against all forms of Kratom prescriptions and over-the-counter medications due to the lack of evidence demonstrating its safety or efficacy, and has prohibited the marketing of Kratom in any form for use in the United States. Typically, because consumers do not have sufficient knowledge regarding the applicable regulatory issues, they are easily persuaded by merchants’ statements regarding the effectiveness and/or safety of Kratom.
Regulatory authorities like the AMA and Food and Drug Administration have the responsibility to ensure that supplement manufacturers demonstrate safety and accuracy before their products are marketed to consumers. The need for regulatory oversight is essential in order to protect consumers from preventable harm caused by kratom and other dietary supplements. The Frontiers Review also calls for improved regulation and surveillance of dietary supplements, including more research to inform policy, clearer standards of safety, and more meaningful guidance. Additional measures are needed to regulate kratom to protect consumers from avoidable harm.
To conclude, there is little regulation regarding dietary supplements allowing for unsafe products like Kratom to prosper. Consumers may be misled, placed in unsafe situations, and not have proper protections. Increasing oversight is necessary to provide assurance to consumers that dietary supplements sold in the U.S. will be manufactured safely, have adequate labeling, and be backed up by science as opposed to relying on chance regarding the public’s health.
Leave a Reply